<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568529</url>
  </required_header>
  <id_info>
    <org_study_id>XELOX-AGC</org_study_id>
    <nct_id>NCT00568529</nct_id>
  </id_info>
  <brief_title>Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer</brief_title>
  <official_title>Phase II Study on Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and overall survival of the regimen of&#xD;
      XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory&#xD;
      gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The result of treatment in relapsed and refractory gastric cancer is still not satisfactory.&#xD;
      For the moment, the combination of 5-Fu and cisplatin is regularly used. Capecitabine and&#xD;
      Oxaliplatin are new generation drugs of 5-Fu and cisplatin. The current study is to evaluate&#xD;
      the efficacy and toxicity of this combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    There are not enough patients enrolled.&#xD;
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression and overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Combine Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX(Xeloda and oxaliplatin combination)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Oxaliplatin</intervention_name>
    <description>Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w</description>
    <arm_group_label>Combine Chemotherapy</arm_group_label>
    <other_name>XELOX(Xeloda and oxaliplatin combination)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years&#xD;
&#xD;
          -  Patients with histologically confirmed, unresectable, recurrent and/or metastatic&#xD;
             gastric adenocarcinoma&#xD;
&#xD;
          -  ECOG performance status ≤1&#xD;
&#xD;
          -  Measurable diseases according to the RECIST&#xD;
&#xD;
          -  Relapse or refractory after the first-line chemotherapy&#xD;
&#xD;
          -  Sign ICF,normal laboratory findings:absolute neutrophil count and platelet count ≥&#xD;
             2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL,&#xD;
             transaminases ≤ 1.5 times upper normal limit) and renal function (calculated&#xD;
             creatinine clearance ≥ 60 ml/min).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relapse within 6 months after adjuvant chemotherapy which contained oxaliplatin&#xD;
&#xD;
          -  Have used any of drugs in the regimen in first-line chemotherapy&#xD;
&#xD;
          -  Pregnant or lactating women,serious uncontrolled diseases and intercurrent infection&#xD;
&#xD;
          -  The evidence of CNS metastasis&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix&#xD;
&#xD;
          -  Received other chemotherapy regimen after metastasis&#xD;
&#xD;
          -  Participated in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University cancer hospital</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>Advanced gastric cancer</keyword>
  <keyword>Response rate</keyword>
  <keyword>Side effects</keyword>
  <keyword>time to progression</keyword>
  <keyword>overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

